BiotechTube

Rituximab + CHOP + CVP + Ibritumomab Tiuxetan

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkins Lymphoma

Conditions

Non-Hodgkins Lymphoma

Trial Timeline

Apr 1, 2002 → Jan 1, 2009

NCT ID
NCT00193440

About Rituximab + CHOP + CVP + Ibritumomab Tiuxetan

Rituximab + CHOP + CVP + Ibritumomab Tiuxetan is a phase 2 stage product being developed by Biogen for Non-Hodgkins Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00193440. Target conditions include Non-Hodgkins Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00193440Phase 2Completed

Competing Products

15 competing products in Non-Hodgkins Lymphoma

See all competitors
ProductCompanyStageHype Score
Acalabrutinib + ACP-319AstraZenecaPhase 1/2
41
JBH492NovartisPhase 1
33
Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2CRochePhase 1/2
41
Obinutuzumab + Glofitamab + Gemcitabine + OxaliplatinRochePhase 2
52
Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + RituximabAmgenPhase 2
51
hLL2 (epratuzumab)Gilead SciencesPhase 1
32
Velcade + TemsirolimusPfizerPhase 2
51
alemtuzumabSanofiPhase 1/2
40
Odronextamab + REGN5837Regeneron PharmaceuticalsPhase 1
32
Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + FludarabineBayerPhase 1/2
38
Rituximab + Fludarabine + CAMPTH-1HBayerPhase 2
49
Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y ZevalinBiogenPhase 2
49
UblituximabTG TherapeuticsPhase 1/2
38
Ublituximab + LenalidomideTG TherapeuticsPhase 1
30
XmAb13676XencorPhase 1
28

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved
82
Dimethyl fumarateApproved
82
[18F]Florbetapir PET imagingApproved
82
dimethyl fumarateApproved
82
ibritumomab tiuxetan (Zevalin®)Approved
82